<DOC>
	<DOCNO>NCT02805738</DOCNO>
	<brief_summary>A Multicenter , Randomized , Double-blind , Parallel Design , Phase III Clinical Trial Evaluate Efficacy Safety CKD-390 tablet</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety CKD-390 Tablet</brief_title>
	<detailed_description>A Multicenter , Randomized , Double-blind , Parallel Design , Phase III Clinical Trial Evaluate Efficacy Safety CKD-390 tablet Viread® tablet Chronic hepatitis B Patients Subjects receive either single oral dose test formulation ( CKD-390 ) oral dose reference formulation ( viread ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1. male female old 19 year time screen 2 . Patients chronic hepatitis B disease take Viried 6 month 3 . Patients show HBV DNA undetected ( less 20 IU/mL ) 4 . Patients show positive HBsAg 5 . Patients show positive HBeAg negative HBeAg 6 . Patients fully understand clinical trial indepth explanation , decide join clinical trial sign inform consent 1 . Patients take antiviral agent except Viread Tab 2 . Patients hepatitis C ( HCV ) , hepatitis D ( HDV ) , human immunodeficiency virus ( HIV ) 3 . Patients seroperitoneum , icterus , hepatic encephalopathy , variceal hemorrhage Patients follow value screen total bilirubin &gt; Upper normal limit x 1.5 prothrombin time ( INR ) &gt; Upper normal limit x 1.5 platelet &lt; 75,000/ul serum albumin &lt; 3.0g/dl 4 . Patients estimate hepatocellular carcinoma ( HCC ) image examination show alphafetoprotein ( AFP ) 50ng/mL 5 . Patients show Creatinine Clearance &lt; 50 mL/min calculate CockcroftGault equation 6 . Patients disease like heart failure , renal failure , pancreatitis investigator consider ineligible study 7 . Patients hepatic disease like hematochromatosis , Wilson 's disease , alcoholic cirrhosis , autoimmune hepatic disease , α1 antitrypsin deficit syndrome 8 . Patients genetic disease like Galactose intolerance , lapplactase deficiency , Glucosegalactose malabsorption 9 . History malignant tumor within 5 year 10 . Patients take investigational product within 30 day 11 . Patients administer immunosuppressant Nephrotoxic drug , Hepatotoxic drug period Clinical Trial 12 . Pregnant , breastfeed childbearing age n't use adequate contraception 13 . Patients receive organ transplant bone marrow transplant go receive surgury 14 . History allergic reaction investigational product 15 . Patients investigator consider ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>tenofovir</keyword>
	<keyword>CKD-390</keyword>
</DOC>